Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Cocrystal Pharma, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, Gary Wilcox, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. | The annual report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and | |
2. | The information contained in the annual report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ Gary Wilcox | |
Gary Wilcox | |
Interim Chief Executive Officer | |
(Principal Executive Officer) | |
Dated: March 21, 2018 |
In connection with the annual report of Cocrystal Pharma, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, James Martin, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. | The annual report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and | |
2. | The information contained in the annual report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ James Martin | |
James Martin | |
Chief Financial Officer | |
(Principal Financial Officer) | |
Dated: March 21, 2018 |